Moderna, Inc. Research and Development Expense
Moderna, Inc. (MRNA) reported Research and Development Expense of $651.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-31
- Moderna, Inc. research and development expense for the quarter ending 2026-06-30 was $651.00M, a 7.00% decline year-over-year.
- Moderna, Inc. research and development expense for the quarter ending 2026-03-31 was $649.00M, a 24.18% decline year-over-year.
- Moderna, Inc. research and development expense for the quarter ending 2025-12-31 was $775.00M, a 30.93% decline year-over-year.
- Moderna, Inc. research and development expense for the quarter ending 2025-09-30 was $801.00M, a 29.55% decline year-over-year.
- Moderna, Inc. research and development expense for fiscal 2025 was $3.13B, a 31.06% decline from fiscal 2024.
- Moderna, Inc. research and development expense for fiscal 2024 was $4.54B, a 6.23% decline from fiscal 2023.
- Moderna, Inc. research and development expense for fiscal 2023 was $4.84B, a 47.04% increase from fiscal 2022.
- Moderna, Inc. research and development expense for fiscal 2022 was $3.29B, a 65.49% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $651.00M 10-Q · filed 2026-07-31 | $1.30B 10-Q · filed 2026-07-31 | $2.08B derived: sum of 3 quarters · filed 2026-07-31 | $2.88B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | $649.00M 10-Q · filed 2026-05-01 | $1.42B derived: sum of 2 quarters · filed 2026-05-01 | $2.23B derived: sum of 3 quarters · filed 2026-05-01 | $2.92B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-12-31 | $775.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.58B derived: sum of 2 quarters · filed 2026-02-20 | $2.28B derived: sum of 3 quarters · filed 2026-07-31 | $3.13B 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | $801.00M 10-Q · filed 2025-11-06 | $1.50B derived: sum of 2 quarters · filed 2026-07-31 | $2.36B 10-Q · filed 2025-11-06 | $3.48B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-06-30 | $700.00M 10-Q · filed 2026-07-31 | $1.56B 10-Q · filed 2026-07-31 | $2.68B derived: sum of 3 quarters · filed 2026-07-31 | $3.81B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-03-31 | $856.00M 10-Q · filed 2026-05-01 | $1.98B derived: sum of 2 quarters · filed 2026-05-01 | $3.12B derived: sum of 3 quarters · filed 2026-05-01 | $4.34B derived: sum of 4 quarters · filed 2026-05-01 | ||||
| 2024-12-31 | $1.12B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $2.26B derived: sum of 2 quarters · filed 2026-02-20 | $3.48B derived: sum of 3 quarters · filed 2026-02-20 | $4.54B 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | $1.14B 10-Q · filed 2025-11-06 | $2.36B derived: sum of 2 quarters · filed 2025-11-06 | $3.42B 10-Q · filed 2025-11-06 | $4.83B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | $1.22B 10-Q · filed 2025-08-01 | $2.28B 10-Q · filed 2025-08-01 | $3.69B derived: sum of 3 quarters · filed 2026-02-20 | $4.85B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | $1.06B 10-Q · filed 2025-05-01 | $2.47B derived: sum of 2 quarters · filed 2026-02-20 | $3.63B derived: sum of 3 quarters · filed 2026-02-20 | $4.78B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | $1.41B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $2.57B derived: sum of 2 quarters · filed 2026-02-20 | $3.71B derived: sum of 3 quarters · filed 2026-02-20 | $4.84B 10-K · filed 2026-02-20 | ||||
| 2023-09-30 | $1.16B 10-Q · filed 2024-11-07 | $2.31B derived: sum of 2 quarters · filed 2024-11-07 | $3.44B 10-Q · filed 2024-11-07 | $4.65B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-06-30 | $1.15B 10-Q · filed 2024-08-01 | $2.28B 10-Q · filed 2024-08-01 | $3.49B derived: sum of 3 quarters · filed 2025-02-21 | $4.31B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-03-31 | $1.13B 10-Q · filed 2024-05-02 | $2.34B derived: sum of 2 quarters · filed 2025-02-21 | $3.16B derived: sum of 3 quarters · filed 2025-02-21 | $3.87B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2022-12-31 | $1.21B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $2.03B derived: sum of 2 quarters · filed 2025-02-21 | $2.74B derived: sum of 3 quarters · filed 2025-02-21 | $3.29B 10-K · filed 2025-02-21 | ||||
| 2022-09-30 | $820.00M 10-Q · filed 2023-11-03 | $1.53B derived: sum of 2 quarters · filed 2023-11-03 | $2.08B 10-Q · filed 2023-11-03 | $2.73B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-06-30 | $710.00M 10-Q · filed 2023-08-03 | $1.26B 10-Q · filed 2023-08-03 | $1.91B derived: sum of 3 quarters · filed 2024-02-23 | $2.43B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-03-31 | $554.00M 10-Q · filed 2023-05-04 | $1.20B derived: sum of 2 quarters · filed 2024-02-23 | $1.72B derived: sum of 3 quarters · filed 2024-02-23 | $2.14B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2021-12-31 | $648.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $1.17B derived: sum of 2 quarters · filed 2024-02-23 | $1.59B derived: sum of 3 quarters · filed 2024-02-23 | $1.99B 10-K · filed 2024-02-23 | ||||
| 2021-09-30 | $521.00M 10-Q · filed 2022-11-03 | $942.00M derived: sum of 2 quarters · filed 2022-11-03 | $1.34B 10-Q · filed 2022-11-03 | $2.10B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-06-30 | $421.00M 10-Q · filed 2022-08-03 | $822.00M 10-Q · filed 2022-08-03 | $1.58B derived: sum of 3 quarters · filed 2023-02-24 | $1.93B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-03-31 | $401.00M 10-Q · filed 2022-05-04 | $1.16B derived: sum of 2 quarters · filed 2023-02-24 | $1.50B derived: sum of 3 quarters · filed 2023-02-24 | $1.66B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2020-12-31 | $759.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $1.10B derived: sum of 2 quarters · filed 2023-02-24 | $1.25B derived: sum of 3 quarters · filed 2023-02-24 | $1.37B 10-K · filed 2023-02-24 | $1.37B 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $344.00M 10-Q · filed 2021-11-04 | $344.49M 10-Q · filed 2020-10-30 | $496.00M derived: sum of 2 quarters · filed 2021-11-04 | $611.00M 10-Q · filed 2021-11-04 | $611.48M 10-Q · filed 2020-10-30 | $728.64M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-06-30 | $152.00M 10-Q · filed 2021-08-05 | $151.86M 10-Q · filed 2020-08-06 | $267.00M 10-Q · filed 2021-08-05 | $266.99M 10-Q · filed 2020-08-06 | $384.64M derived: sum of 3 quarters · filed 2022-02-25 | $504.28M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-03-31 | $115.00M 10-Q · filed 2021-05-06 | $115.14M 10-Q · filed 2020-05-07 | $232.65M derived: sum of 2 quarters · filed 2022-02-25 | $352.28M derived: sum of 3 quarters · filed 2022-02-25 | $480.59M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2019-12-31 | $117.64M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $237.28M derived: sum of 2 quarters · filed 2022-02-25 | $365.59M derived: sum of 3 quarters · filed 2022-02-25 | $496.00M 10-K · filed 2022-02-25 | $496.31M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $119.64M 10-Q · filed 2020-10-30 | $119.72M 10-Q · filed 2019-11-06 | $247.94M derived: sum of 2 quarters · filed 2020-10-30 | $378.36M 10-Q · filed 2020-10-30 | $378.79M 10-Q · filed 2019-11-06 | $528.78M derived: sum of 4 quarters · filed 2021-02-26 | ||
| 2019-06-30 | $128.31M 10-Q · filed 2020-08-06 | $128.50M 10-Q · filed 2019-08-08 | $258.72M 10-Q · filed 2020-08-06 | $259.07M 10-Q · filed 2019-08-08 | $409.15M derived: sum of 3 quarters · filed 2021-02-26 | $518.20M derived: sum of 4 quarters · filed 2021-02-26 | ||
| 2019-03-31 | $130.41M 10-Q · filed 2020-05-07 | $130.57M 10-Q · filed 2019-05-09 | $280.84M derived: sum of 2 quarters · filed 2021-02-26 | $389.89M derived: sum of 3 quarters · filed 2021-02-26 | $494.37M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2018-12-31 | $150.43M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $259.48M derived: sum of 2 quarters · filed 2021-02-26 | $363.96M derived: sum of 3 quarters · filed 2021-02-26 | $454.08M 10-K · filed 2021-02-26 | ||||
| 2018-09-30 | $109.05M 10-Q · filed 2019-11-06 | $213.53M derived: sum of 2 quarters · filed 2019-11-06 | $303.65M 10-Q · filed 2019-11-06 | |||||
| 2018-06-30 | $104.48M 10-Q · filed 2019-08-08 | $194.60M 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | $90.12M 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | $410.46M 10-K · filed 2020-02-27 | |||||||
| 2016-12-31 | $274.72M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |